Leap Therapeutics Inc(LPTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LPTX Leap Therapeutics Inc

Market Closed 11-12 16:00:00 EST

2.05

+0.00

0.00%

High2.05	Low2.05	Vol0.00
Open2.05	D1 Closing2.05	Amplitude0.00%
Mkt Cap116.14M	Tradable Cap102.25M	Total Shares56.65M
T/O1.04B	T/O Rate0.00%	Tradable Shares49.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LPTX","market":"US","secType":"STK","nameCN":"Leap Therapeutics Inc","latestPrice":2.05,"timestamp":1762981200000,"preClose":2.05,"halted":8,"volume":0,"delay":0,"floatShares":49877123,"shares":56651840,"eps":-1.600252,"marketStatus":"Market Closed","change":0,"latestTime":"11-12 16:00:00 EST","open":2.05,"high":2.05,"low":2.05,"amount":1040200199.9260579,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.600252,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"symbolChange":{"newSymbol":"CYPH","executeDate":"2025-11-13"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.05,"volumeRatio":0},"requestUrl":"/m/hq/s/LPTX","defaultTab":"news","newsList":[{"id":"2583630511","title":"Why Leap Therapeutics Stock (LPTX) Is in the News","url":"https://stock-news.laohu8.com/highlight/detail?id=2583630511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583630511?lang=en_us&edition=fundamental","pubTime":"2025-11-14 04:45","pubTimestamp":1763066700,"startTime":"0","endTime":"0","summary":"U.S.-based Leap Therapeutics ($LPTX) shocked investors with a 368.6% surge in its stock on Wednesday. However, in pre-market trading on Thursday, L...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/whats-behind-the-jaw-dropping-rally-in-leap-therapeutics-stock-lptx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/whats-behind-the-jaw-dropping-rally-in-leap-therapeutics-stock-lptx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","BK4563","LPTX"],"gpt_icon":0},{"id":"2583359417","title":"What's Going On With Leap Therapeutics Stock On Thursday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2583359417","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583359417?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:02","pubTimestamp":1763046120,"startTime":"0","endTime":"0","summary":"Leap Therapeutics shares are plunging after rebranding as Cypherpunk, pivoting to a Zcash treasury and announcing a $200M stock offering.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/13/Leap-Therapeutics.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/13/Leap-Therapeutics.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/11/48835777/whats-going-on-with-leap-therapeutics-stock-on-thursday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/11/48835777/whats-going-on-with-leap-therapeutics-stock-on-thursday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4007","BK4139","BK4563","LPTX","BK4539","LENZ","BK4505"],"gpt_icon":0},{"id":"2583267306","title":"Crude Oil Dips 4%; On Holding Shares Jump After Q3 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2583267306","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583267306?lang=en_us&edition=fundamental","pubTime":"2025-11-13 01:18","pubTimestamp":1762967899,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/11/48811415/crude-oil-dips-4-on-holding-shares-jump-after-q3-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMCT","BK4194","BK4204","BK4585","USJW.SI","LU0472753341.HKD","LU0289739343.SGD","BK4223","BK4505","CYPH","VSA","ONON","BK4139","MNQmain","LU1804176565.USD","BK4561","USAW.SI","QID","LU0057025933.USD","SQQQ","LFS","LU0289961442.SGD","BK4563","NQmain","LPTX","TQQQ","BK4588","QLD","LU0069063385.USD",".IXIC","PSQ","NRGV","SLRX","NVIW.SI","BK4182","BK4146","BK4547","LU0511384066.AUD","LU2265009873.SGD","TSYW.SI"],"gpt_icon":1},{"id":"2582372798","title":"Leap Therapeutics Inc: May Offer, Sell Shares of Common Stock of up to $200 Mln From Time to Time","url":"https://stock-news.laohu8.com/highlight/detail?id=2582372798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582372798?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:14","pubTimestamp":1762956898,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO0QZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","CYPH","LPTX","BK4505","BK4139"],"gpt_icon":0},{"id":"2582622371","title":"Cypherpunk Technologies' Q3 net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2582622371","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582622371?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:13","pubTimestamp":1762953220,"startTime":"0","endTime":"0","summary":"Cypherpunk Technologies' Q3 net loss narrowsOverviewCypherpunk Technologies reports Q3 net loss of $3.3 mln, down from $18.2 mln last yearCompany acquires 203,775 ZEC for $50 mln as part of digital as","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0GD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LPTX","BK4139","BK4563","BK4505","CYPH"],"gpt_icon":0},{"id":"2582012373","title":"Leap Therapeutics Names Khing Oei Chairman and Will McEvoy Chief Investment Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582012373","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582012373?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:02","pubTimestamp":1762948973,"startTime":"0","endTime":"0","summary":"Leap Therapeutics Inc. has announced key management changes as part of its rebranding to Cypherpunk Technologies Inc. Khing Oei has been appointed Chairman of the Board, and Will McEvoy has been named Chief Investment Officer and Board member, both effective November 11, 2025. Christopher Mirabelli, PhD, will step down as Chairman but remain on the Board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on November 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL3XRVRN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","BK4505","CYPH","LPTX"],"gpt_icon":0},{"id":"2582373046","title":"Leap Therapeutics Rebrands as Cypherpunk Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373046","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373046?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:02","pubTimestamp":1762948945,"startTime":"0","endTime":"0","summary":"Leap Therapeutics Inc. has announced it will change its name to Cypherpunk Technologies Inc. and will adopt a new ticker symbol, CYPH, as part of a rebranding initiative focused on a digital asset treasury strategy centered on Zcash .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via CNW  on November 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLJF43w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYPH","LPTX","BK4505","BK4139","BK4563"],"gpt_icon":0},{"id":"2582739533","title":"Leap Therapeutics Inc: Cypherpunk Technologies Inc. Announces Acquisition of 203,775.27 Zec.","url":"https://stock-news.laohu8.com/highlight/detail?id=2582739533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582739533?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948807,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO087:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4505","CYPH","BK4139","LPTX"],"gpt_icon":0},{"id":"2582373667","title":"Leap Therapeutics Inc: Khing Oei Appointed Chairman of Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373667","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373667?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948807,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO087:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CYPH","LPTX","BK4563","BK4505"],"gpt_icon":0},{"id":"2582373400","title":"Leap Therapeutics: Co Will Begin Trading Under Its New Name & Ticker Symbol Cyph on November 13","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373400","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373400?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948807,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO087:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYPH","BK4563","BK4505","LPTX","BK4139"],"gpt_icon":0},{"id":"2581819878","title":"Leap Therapeutics Inc  expected to post a loss of 24 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581819878","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581819878?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:44","pubTimestamp":1762526659,"startTime":"0","endTime":"0","summary":"Leap Therapeutics Inc  expected to post a loss of24cents a share - Earnings Preview Leap Therapeutics Inc LPTX.OQ LPTX.O is expected to  show no change in quarterly revenue when it reports  results on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ1ZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LPTX","BK4505","BK4139","BK4563","CYPH"],"gpt_icon":0},{"id":"2578252849","title":"Leap Therapeutics Inc. Announces Date for Upcoming Special Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2578252849","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578252849?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:59","pubTimestamp":1761339550,"startTime":"0","endTime":"0","summary":"Leap Therapeutics Inc. will hold a special meeting of stockholders virtually on December 15, 2025. During the meeting, shareholders will vote on five proposals: approval of an authorized share increase, approval of a reverse stock split, approval of the Leap Therapeutics, Inc. 2025 Equity Incentive Plan, approval of a private placement issuance, and authorization to adjourn the special meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 24, 2025, and is solely responsible for the information contained there","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL3JjD0c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","BK4505","LPTX"],"gpt_icon":0},{"id":"2576853490","title":"Leap Therapeutics Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2576853490","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576853490?lang=en_us&edition=fundamental","pubTime":"2025-10-20 19:01","pubTimestamp":1760958063,"startTime":"0","endTime":"0","summary":"Leap Therapeutics Inc. announced the final results from Part B of the DeFianCe study, a Phase 2 clinical trial evaluating sirexatamab , an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy for patients with microsatellite stable  colorectal cancer who have received one prior systemic therapy for advanced disease. The final data were presented at the European Society for Medical Oncology  Congress 2025. In the DKK1-high patient population, the objective response rate  was 38.0% in the Sirexatamab Arm compared to 23.7% in the control arm. Leap Therapeutics plans to continue supporting the development of sirexatamab in DKK1-high colorectal cancer patients and to engage with regulatory authorities regarding its potential registrational path.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpose","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL9Cctc3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","LPTX","BK4505","BK4139"],"gpt_icon":0},{"id":"2574156191","title":"Press Release: Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2574156191","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574156191?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:00","pubTimestamp":1760007600,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Oct. 9, 2025 /PRNewswire/ -- Leap Therapeutics , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has closed its previously announced private placement led by Winklevoss Capital raising $58,888,888 in cash to initiate a digital asset treasury strategy. At the closing of the transaction, Leap issued  15,212,311 shares of common stock ,  pre-funded warrants  to purchase up to an aggregate of 80,768,504 shares of common stock, and  warrants to purchase an additional 71,985,605 shares of common stock at an exercise price of $0.5335 per share .Winklevoss Capital will provide both capital and strategic support to help Leap structure and execute its digital asset treasury strategy. Leveraging the expertise of Winklevoss Capital, Leap aims to build long-term shareholder value through participation in digital assets. A portion of the capital will be used to continue development of Leap's therapeutic programs, incl","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["US30Y.BOND","NQmain","US6M.BOND","BK4139","LPTX","TMF","US10Y.BOND","US12M.BOND","US7Y.BOND","US3Y.BOND","BK4007","BK4563","BK4505","BK4539","LENZ","TLTW","US5Y.BOND","US2Y.BOND"],"gpt_icon":1},{"id":"2573395306","title":"Why Is Leap Therapeutics Down 9% In Pre-Market Trading?","url":"https://stock-news.laohu8.com/highlight/detail?id=2573395306","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573395306?lang=en_us&edition=fundamental","pubTime":"2025-10-07 16:55","pubTimestamp":1759827300,"startTime":"0","endTime":"0","summary":"Leap Therapeutics is trading lower in pre-market following a $58.9 million private placement led by Winklevoss Capital.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/07/Stockmarket-Online-Trading-Chart-Candles.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/07/Stockmarket-Online-Trading-Chart-Candles.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/10/48061531/why-is-leap-therapeutics-down-9-in-pre-market-trading","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/10/48061531/why-is-leap-therapeutics-down-9-in-pre-market-trading","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4007","BK4139","BK4563","LPTX","BK4539","LENZ","BK4505"],"gpt_icon":1},{"id":"2573670141","title":"Leap Therapeutics announces $58.88M private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2573670141","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573670141?lang=en_us&edition=fundamental","pubTime":"2025-10-06 21:10","pubTimestamp":1759756205,"startTime":"0","endTime":"0","summary":"Leap Therapeutics (LPTX) announced $58,888,888 in cash commitments for a private investment in public equity offering led by Winklevoss Capital to ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/leap-therapeutics-announces-58-88m-private-placement-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/leap-therapeutics-announces-58-88m-private-placement-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4563","BK4007","LENZ","BK4505","LPTX","BK4139"],"gpt_icon":0},{"id":"2573677742","title":"Leap Therapeutics Announces $58.9 Million Private Placement Led by Winklevoss Capital to Launch Digital Asset Treasury Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2573677742","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573677742?lang=en_us&edition=fundamental","pubTime":"2025-10-06 21:02","pubTimestamp":1759755737,"startTime":"0","endTime":"0","summary":"Leap Therapeutics Announces $58.9 Million Private Placement Led by Winklevoss Capital to Launch Digital Asset Treasury Strategy. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on October 06, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL5bvKpc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","BK4505","LPTX"],"gpt_icon":0},{"id":"2566991185","title":"Leap Therapeutics Inc. Faces Nasdaq Delisting Risk Over Stock Price Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2566991185","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566991185?lang=en_us&edition=fundamental","pubTime":"2025-09-12 04:31","pubTimestamp":1757622705,"startTime":"0","endTime":"0","summary":"Leap Therapeutics Inc. has announced a regulatory issue concerning its continued listing on The Nasdaq Capital Market. The company received a notification from Nasdaq indicating that its common stock has consistently fallen below the minimum closing bid price of $1.00 per share, a requirement under Nasdaq Listing Rule 5550. As of March 12, 2025, Leap Therapeutics was given 180 days to rectify this by maintaining the minimum bid price for at least 10 consecutive business days, with a deadline set for September 8, 2025. The company has since requested an additional 180-day compliance period, which extends to March 9, 2026, to address the issue. Leap Therapeutics is considering options, including a reverse stock split, to meet the requirements. Failure to comply could result in delisting, although the company retains the right to appeal Nasdaq's decision.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL1tSqj6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4505","LPTX","BK4139"],"gpt_icon":0},{"id":"2559954053","title":"BRIEF-Leap Therapeutics Reports Second Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2559954053","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559954053?lang=en_us&edition=fundamental","pubTime":"2025-08-14 20:07","pubTimestamp":1755173275,"startTime":"0","endTime":"0","summary":"BRIEF-Leap Therapeutics Reports Second Quarter Financial ResultsAug 14 (Reuters) - Leap Therapeutics Inc LPTX.O:LEAP THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTSLEAP THERAPEUTICS INC - I","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nTUA6DWNWK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LPTX","BK4505","BK4139","BK4563"],"gpt_icon":0},{"id":"2559959294","title":"Leap Therapeutics Reports Q2 2025 Net Loss of $16.6M, Down from $20.4M in Q2 2024; R&D Expenses Decrease by $7.4M","url":"https://stock-news.laohu8.com/highlight/detail?id=2559959294","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559959294?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:01","pubTimestamp":1755169298,"startTime":"0","endTime":"0","summary":"Leap Therapeutics Inc. has released its financial results for the second quarter of 2025. The company reported a net loss of $16.6 million, an improvement from the $20.4 million net loss experienced during the same period in 2024. This decrease in net loss was largely attributed to a reduction in research and development and general and administrative expenses, although it was partially offset by restructuring charges due to a workforce reduction. Research and development expenses for the second quarter of 2025 were $10.5 million, down from $17.9 million in the second quarter of 2024. This $7.4 million decrease resulted from lower clinical trial costs, payroll and headcount-related expenses, manufacturing costs, and stock-based compensation expenses. Significant business updates include the company's strategic restructuring, which involved a 75% workforce reduction aimed at preserving capital. Additionally, the Board of Directors has initiated a process to explore strategic alternative","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDL4R1GxG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU1363072403.SGD","BK4505","BK4139","BK4127","LPTX","IE00B64PRP62.GBP","LU2265009873.SGD","BK4585","LU0971096721.USD","BK4588","LU1804176565.USD","BK4563","RJF","IE00BGHQF748.EUR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leaptx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":5.8654},{"period":"6month","weight":4.0012},{"period":"1year","weight":-0.345},{"period":"ytd","weight":-0.287}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.027306},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.021879},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.077902},{"month":4,"riseRate":0.444444,"avgChangeRate":0.024066},{"month":5,"riseRate":0.333333,"avgChangeRate":0.10817},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.10012},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.017339},{"month":8,"riseRate":0.333333,"avgChangeRate":0.008005},{"month":9,"riseRate":0.444444,"avgChangeRate":0.109211},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.026459},{"month":11,"riseRate":0.333333,"avgChangeRate":0.323596},{"month":12,"riseRate":0.5,"avgChangeRate":0.157619}],"exchange":"NASDAQ","name":"Leap Therapeutics Inc","nameEN":"Leap Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Leap Therapeutics Inc(LPTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Leap Therapeutics Inc(LPTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Leap Therapeutics Inc,LPTX,Leap Therapeutics Inc股票,Leap Therapeutics Inc股票老虎,Leap Therapeutics Inc股票老虎国际,Leap Therapeutics Inc行情,Leap Therapeutics Inc股票行情,Leap Therapeutics Inc股价,Leap Therapeutics Inc股市,Leap Therapeutics Inc股票价格,Leap Therapeutics Inc股票交易,Leap Therapeutics Inc股票购买,Leap Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Leap Therapeutics Inc(LPTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Leap Therapeutics Inc(LPTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}